Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USZ-STRIKE: SRS + Systemic Therapy for Brain Metastases in Melanoma or NSCLC
NCT05522660Phase 3Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Nov 2022
- Primary completion
- Sep 2026
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in melanoma, non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Central Nervous System-specific Progression-Free Survival up to 42 months. Started Nov 2022; status: recruiting.
02
Conditions
melanomanon-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT05522660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522660.